Skip NavigationSkip to Content

Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles

  1. Author:
    Pinto, L. A.
    Edwards, J.
    Castle, P. E.
    Harro, C. D.
    Lowy, D. R.
    Schiller, J. T.
    Wallace, D.
    Kopp, W.
    Adelsberger, J. W.
    Baseler, M. W.
    Berzofsky, J. A.
    Hildesheim, A.
  2. Author Address

    NCI Frederick, SAIC Frederick Inc, Bldg 469,Rm 120, Frederick, MD 21702 USA NCI Frederick, SAIC Frederick Inc, Frederick, MD 21702 USA NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA Johns Hopkins Univ, Baltimore, MD USA Pinto LA NCI Frederick, SAIC Frederick Inc, Bldg 469,Rm 120, Frederick, MD 21702 USA
    1. Year: 2003
  1. Journal: Journal of Infectious Diseases
    1. 188
    2. 2
    3. Pages: 327-338
  2. Type of Article: Article
  1. Abstract:

    The causal association between papillomavirus (HPV) infection and cervical cancer has been demonstrated; the development of a prophylactic vaccine to protect against HPV infection may therefore reduce the incidence of this cancer worldwide. Noninfectious HPV-like particles (VLPs), composed of the L1 major capsid protein, are current candidate vaccines for prevention of HPV infection and cervical neoplasia. Although neutralizing antibodies have a pivotal role in the prevention of initial infection, cellular immune responses to HPV antigens may have an important role in viral clearance. A phase II trial was conducted to further evaluate the immunogenicity of a recombinant HPV-16 L1 VLP vaccine administered intramuscularly, without adjuvant, at 0, 1, and 6 months. Cell-mediated immune responses (lymphoproliferation and cytokine production) to HPV- 16 L1 VLPs were evaluated in peripheral blood mononuclear cells (PBMCs) from 43 individuals receiving the L1 VLP vaccine and from 10 individuals receiving placebo. Vaccination resulted, at months 2 and 7 (i.e., 1 month after the second immunization and 1 month after third immunization, respectively), in increases in T cell - proliferative response to HPV-16 L1 VLPs (P < .001). In addition, significant increases in cytokine (interferon-γ, interleukin [IL]-5 and IL-10) responses to L1 VLPs were observed after vaccination (P < .001). The strongest cytokine responses at month 7 were observed in individuals with high antibody titers at month 2, suggesting that neutralizing antibodies generated by initial vaccination may augment T cell responses to subsequent booster vaccinations. No significant increases in lymphoproliferative or cytokine responses to L1 VLPs were observed in individuals receiving placebo. In summary, the HPV-16 L1 vaccine induces not only robust B cell responses but also L1-specific T cell responses detectable by proliferation of both CD4(+) and CD8(+) T cells and in vitro production of both Th1- and Th2-type cytokines. Future efficacy studies are needed to evaluate whether and/or how VLP vaccines confer protection against genital HPV infection and associated disease.

    See More

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel